The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1445-1450

  Adam, B W ^a   Hall, E M ^a   Sternberg, M ^a   Lim, T H ^a   Flores, S R ^a   O'Brien, S ^a   Simms, D ^a   Li, L X ^a   De Jesus, V R ^a   Hannon, W H ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CDC retired   (United States)

Author keywords

Disorder markers; Dried blood spots; Humidity effects; Newborn screening; Sample stability; Storage conditions; Temperature effects

Indexed keywords

ACETYLCARNITINE; ARGININE; BIOTINIDASE; CARNITINE DERIVATIVE; CITRULLINE; GALACTOSE; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; HYDROXYPROGESTERONE; LEUCINE; METHIONINE; PALMITOYLCARNITINE; PHENYLALANINE; PROPIONYLCARNITINE; SUCCINYLACETONE; THYROTROPIN; THYROXINE; TRYPSINOGEN; TYROSINE; VALINE;

AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEGRADATION; DRIED BLOOD SPOT; ELUTION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEAT; HUMAN; HUMIDITY; NEWBORN; NEWBORN DISEASE; NEWBORN SCREENING; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; STORAGE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; UNITED STATES;

ARGININE; BIOLOGICAL MARKERS; BIOTINIDASE; CARNITINE; DRIED BLOOD SPOT TESTING; ENZYME STABILITY; HEPTANOATES; HUMANS; HUMIDITY; INFANT, NEWBORN; MYRISTIC ACIDS; NEONATAL SCREENING; PRESERVATION, BIOLOGICAL; PROTEIN STABILITY; UNITED STATES; UTP-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE;

EID: 81555204325     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.010     Document Type: Article

References (22)

1. Newborn screening: toward a uniform screening panel and system. Genet Med 2006, 8(5):S12-S252. as authored by the American College of Medical Genetics (ACMG) and commissioned by the Health Resources and Services Administration (HRSA).
2. Watson M.S., Mann M.Y., Lloyd-Puryear M.A., Rinaldo P., Howell R.R. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 2006, 117(Suppl):296-307.
3. Sebelius K. Letter from the Secretary of Health and Human Services (accessed July 2011). http://www.hrsa.gov/heritabledisorderscommittee/correspondence/response5_21_2010.pdf.
4. Adam B.W., Hubert I.L., Hannon W.H., Bayse D.D. Quality control program for neonatal hypothyroidism Atlanta (GA). Summary Report I 1980, Centers for Disease Control, Bureau of Laboratories.
5. Levy H.L., Simmons J.R., MacReady R.A. Stability of amino acids and galactose in the newborn screening filter paper blood specimen. J Pediatr 1985, 107:757-760.
6. Waite K.V., Maberly G.F., Eastman C.J. Storage condtions and stability of thyrotropin and thyroid hormones on filter paper. Clin Chem 1987, 33:853-855.
7. Frazier D.M., Clemons E.H., Kirkman H.N. Minimizing false positive diagnoses in newborn screening for galactosemia. Biochem Med Metab Biol 1992, 48:177-178.
8. Zytkovicz T.H., Eaton R.B., Foley T.P., Lister B.C., Rojas D.A., Schwerier M.E. Instability of enzymes, antibodies, and other analytes in dried blood spots - is the major problem heat or humidity. Proceeding of the Eleventh National Symposium on Neonatal Screening; Sept. 12-16, 1995; Corpus Christi, Texas 1995, 293-295. ASTPHLD, Washington, DC. B.L. Therrell, B.G. Aldis (Eds.).
9. Chace D.H., Adam B.W., Smith S.J., Alexander J.R., Hillman S.L., Hannon W.H. Validation of accuracy-based amino acid reference materials in dried-blood spots by tandem mass spectrometry for newborn screening assays. Clin Chem 1999, 45:1269-1277.
10. Freer D.E. Observations on heat/humidity denaturation of enzymes in filter-paper blood spots from newborns. Clin Chem 2005, 51:1060-1062.
11. Li L., Zhou Y., Bell C.J., Earley M.C., Hannon W.H., Mei J.V. Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen. J Med Screen 2006, 13:79-84.
12. Strnadova K.A., Holub M., Muhl A., Heinze G., Ratschmann R., Mascher H., et al. Long-term stability of amino acids and acylcarnitines in dried blood spots. Clin Chem 2007, 53:717-722.
13. Lando V.S., Batista M.C., Nakamura I.T., Mazi C.R., Mendonca B.B., Brito V.N. Effects of long-term storage of filter paper blood samples on neonatal thyroid stimulating hormone, thyroxin, and 17-alpha-hydroxyprogesterone measurements. J Med Screen 2008, 15:109-111.
14. Fingerhut R., Ensenauer R., Roschinger W., Arnecke R., Olgemuller B., Roscher A.A. Stabilities of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 2009, 81:3571-3575.
15. Therrell B.L., Hannon W.H., Pass K.A., Lorey F., Brokopp C., Eckman J., et al. Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Mol Med 1996, 57:116-124.
16. Newborn screening quality assurance program: 2010 annual summary report 2011, 28. CDC, Atlanta.
17. Beutler E., Baluda M.C. A simple spot screening test for galactosemia. J Lab Clin Med 1965, 68:137-141.
18. Heard G.S., Secor McVoy J.R., Wolf B. A screening method for biotinidase deficiency in newborns. Clin Chem 1984, 30:125-127.
19. Orfanos A.P., Jinks D.C., Guthrie R. Microassay for estimation of galactose and galactose-1-phosphate in dried blood specimens. Clin Biochem 1986, 19:225-228.
20. Chace D.H., DiPerna J.C., Mitchell B.L., Sgroi B., Hofman L.F., Naylor E.W. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 2001, 47:1166-1182.
21. Chace D.H., Lim T., Hansen C.R., De Jesus V.R., Hannon W.H. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clin Chim Acta 2009, 407:6-9.
22. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955, 50:1096-1121.